Retinitis Pigmentosa Market: Can 2026’s "Mutation-Agnostic" Gene Therapy Save Vision for All? The year 2026 marks a transformative period in the treatment of Retinitis Pigmentosa (RP) as the industry shifts its focus toward therapies that work regardless of a patient's specific genetic mutation. For years, the only available gene therapy, Luxturna, was limited to a tiny fraction of patients with the RPE65 mutation. However, 2026 is seeing the clinical maturity of "mutation-agnostic"...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
thai
English
French
Spanish
Italiano
Romaian
Portuguese (Brazil)
china